On a per-share basis, the San Diego-based company said it had a loss of 63 cents. Losses, adjusted for asset impairment costs, came to 55 cents per share. The ophthalmic device company posted revenue of ...

Categories: Yahoo FinanceGet free summary analysis TearLab Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of TearLab Corp. – STAAR Surgical Company and CorMedix Inc. (STAA-US and CRMD-US) that have also reported for this period. Highlights Summary numbers: Revenues of CAD 8.18 million, Net Earnings ... Read more
(Read more...)

The San Diego-based company said it had a loss of 67 cents per share. The ophthalmic device company posted revenue of $6.5 million in the period. In the final minutes of trading on Monday, the company's ...

In this analysis, my focus will be on developing a perspective on TearLab Corporation’s (NASDAQ:TEAR) latest ownership structure, a less discussed, but important factor. The impact of a company’s ownershipRead More...

TearLab Corporation (NASDAQ:TEAR), a USD$8.15M small-cap, is a healthcare company operating in an industry, which faces more complex and interdependent challenges, requiring multi-pronged, collaborative, and technology-enabled business models. Healthcare analystsRead More...

The San Diego-based company said it had a loss of 68 cents per share. The ophthalmic device company posted revenue of $7 million in the period, which topped Street forecasts. Three analysts surveyed by ...

Cytori Therapeutics Inc: Should You Catch This Falling Knife? Cytori Therapeutics Inc (NASDAQ:CYTX) shares are crashing over 60% in Monday's trading session, after the biotech company disclosed that its pivotal STAR study assessing Habeo Cell Therapy for the treatment of scleroderma failed to achieve its primary endpoint at week 24 nor any of its secondary endpoints at week 24 or week 48. Kolbert noted, "The totality of the data combined with the investigator comments matter and suggest to us that there maybe a window for approval based on the current data set and/or a small bridging study.

On a per-share basis, the San Diego-based company said it had a loss of 82 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...